{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"513"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"title":"ALT OR AST > 3XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"513"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"title":"ALT OR AST > 5XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"513"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"title":"ALT OR AST > 10XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"513"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"title":"ALT OR AST > 20XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"513"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"title":"TOTAL BILIRUBIN > 2XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"512"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"title":"ALP > 1.5XULN"}],"denoms":[{"counts":[{"groupId":"OG000","value":"513"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"description":"The number of participants experiencing laboratory abnormalities in the specific pre-determined liver tests.","groups":[{"description":"Participants received 480 mg IV Nivolumab in an approximately 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, withdrawal of consent, completion of 12 months of treatment (from first dose of study treatment), disease recurrence, or the study ends, whichever occurred first. Participants began study treatment (Cycle 1) within 3 calendar days of randomization. Subsequent cycles were initiated within ± 3 days of the target visit date.","id":"OG000","title":"Nivolumab"},{"description":"Nivolumab matched placebo (0.9% Sodium Chloride for Injection/5% Dextrose for Injection) IV in a 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, withdrawal of consent, completion of 12 months of treatment (from first dose of study treatment), disease recurrence, or the study ends, whichever occurred first. In the event of disease recurrence, participants on the blinded nivolumab or placebo portion will be offered the option to receive open-label on-protocol nivolumab treatment. Participants received 480 mg IV Nivolumab in a 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, recurrence/progression, withdrawal of consent, completion of 12 months of treatment from first dose of open-label study treatment, whichever occurred first.","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants with at least one on-treatment measurement of the corresponding laboratory parameter","reportingStatus":"POSTED","timeFrame":"From first dose up to 30 days post last dose of the blinded phase (up to 13 months)","title":"Number of Participants Experiencing Laboratory Abnormalities in Selected Liver Parameters","type":"SECONDARY","unitOfMeasure":"Participants"}